A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

NCT00206167 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1600

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Budesonide/formoterol pMDI
DRUG: Formoterol Turbuhaler

Sponsor

AstraZeneca